Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy

Leukemia and Lymphoma

Volumn 55, Issue 1, 2014, Pages 182-187

  Tay, Matthew Rong Jie ^a   Lim, Soon Thye ^b   Tao, Miriam ^b   Quek, Richard Hong Hui ^b   Tay, Kevin ^b   Tan, Thuan Tong ^c  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Asians; Cytomegalovirus; HyperCVAD; Infectious complications; Lymphoma and Hodgkin disease

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; CYTOMEGALOVIRUS INFECTION END ORGAN DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; LUNG EMBOLISM; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; VIRUS REACTIVATION; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SALVAGE THERAPY; SEROTYPING; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891359888     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.798867     Document Type: Article

References (21)

1. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558.
2. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965-981.
3. Crumpacker CS, Heath-Chiozzi M. Overview of cytomegalovirus infections in HIV-infected patients: Current therapies and future strategies. J. Acquir Immune Defi c Syndr 1991; 4(Suppl. 1): S1-S5.
4. Torres HA, Kontoyiannis DP, Aguilera EA, et al. Cytomegalovirus infection in patients with lymphoma: An important cause of morbidity and mortality. Clin Lymphoma Myeloma 2006; 6: 393-398.
5. Han X Y. Epidemiologic analysis of reactivated cytomegalovirus antigenemia in patients with cancer. J. Clin Microbiol 2007; 45: 1126-1132.
6. Ljungman P, Griffiths P, Paya C. Defi nitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
7. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J. Infect Dis 2005; 191: 89-92.
8. Ng AP, Worth L, Chen L, et al. Cytomegalovirus DNAemia and disease: Incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica 2005; 90: 1672-1679.
9. Chemaly RF, Torres HA, Hachem RY, et al. Cytomegalovirus pneumonia in patients with lymphoma. Cancer 2005; 104: 1213-1220.
10. Libby E, Movva S, Quintana D, et al. Cytomegalovirus retinitis during chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone. J. Clin Oncol 2010; 28: E661-e662.
11. Unluturk U, Aksoy S, Yonem O, et al. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkn's lymphoma patient. World J. Gastroenterol 2006; 12: 1978-1979.
12. Seewoodhary J. Cytomegalovirus enterocolitis in a patient with diffuse large B-cell lymphoma after chemotherapy with rituximab. World J. Gastroenterol 2006; 12: 7391.
13. Vallet S, Tempescul A, Tran A, et al. Cytomegalovirus-Associated meningoradiculoneuritis after treatment of mantle cell lymphoma with a combination of chemotherapy and rituximab. Ann Hematol 2005; 84: 545-547.
14. Hill QA, Hill A, Collyns TA, et al. Similar lymphocyte recovery and CMV reactivation profi les between reduced intensity conditioning with alemtuzumab and myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2008; 41: 749-751.
15. Risitano AM, Serio B, Selleri C, et al. Valganciclovir as CMV reactivation prophylaxis in patients receiving alemtuzumab for marrow failure syndromes. Ann Hematol 2009; 88: 1261-1262.
16. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-Transplantation lymphoproliferative disorder. N Engl J. Med 2001; 345: 1000.
17. Sharma M, Moore J, Nguyen V, et al. Fatal CMV pneumonitis in a lymphoma patient treated with rituximab. Am J. Hematol 2009; 84: 614-616.
18. Wijermans PW, Gerrits WB, Haak H L. Severe immunodefi ciency in patients treated with fludarabine monophosphate. Eur J. Haematol 1993; 50: 292-296.
19. Nguyen Q, Estey E, Raad I, et al. Cytomegalovirus pneumonia in adults with leukemia: An emerging problem. Clin Infect Dis 2001; 32: 539-545.
20. Pass RF. Cytomegalovirus. In: Knipe DM, Howley PM, editors. Fields virology, Vol. 2. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001. pp 2675-2705.
21. Sandherr M, Einsele H, Hebart H, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006; 17: 1051-1059.